EP3532059
Brómóhneppa og utan-enda prótínhindra samsetningarmeðferð
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
26.10.2017EP published:
26.1.2022EP application number:
17864117.1
EP translation filed:
21.2.2022Grant published:
15.3.2022EPO information:
European Patent Register
Max expiry date:
25.10.2037Expiry date:
25.10.2025Next due date:
31.10.2025
Title in English:
BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPYLanguage of the patent:
English
Timeline
Today
26.10.2017EP application
26.1.2022EP Publication
21.2.2022Translation submitted
15.3.2022Registration published
25.10.2025Expires
Owner
Name:
Celgene Quanticel Research, Inc.Address:
9393 Towne Centre Drive, San Diego, CA 92129, US
Inventor
Name:
CHO, RobertAddress:
Sunnyvale California 94087, US
Name:
STAFFORD, Jeffrey AlanAddress:
San Diego California 92130, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201662413763 PDate:
27.10.2016Country:
US
Number:
201762560840 PDate:
20.9.2017Country:
US
Classification
Categories:
A61K 31/337, A61K 38/15, A61K 31/472, A61K 31/495, A61K 45/06, A61K 9/00, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 7.9.2022
Expires: 25.10.2023
Payer: Árnason Faktor ehf.
Number: 7
Paid: 13.10.2023
Expires: 25.10.2024
Payer: Árnason Faktor ehf.
Number: 8
Paid: 17.9.2024
Expires: 25.10.2025
Payer: Árnason Faktor ehf.